• Chemotherapy, Part 2

  • Sep 17 2021
  • Length: 33 mins
  • Podcast

  • Summary

  • Welcome to the Ovarian Cancer Education Podcast, a podcast centered around a cancer diagnosis and what that means, a podcast created to help physicians and patients learn from each other, connect, and share stories and knowledge. Today’s episode will focus on chemotherapy for ovarian cancer.


    Show resources:


    Michigan Dept. of Health and Human Services (MDHHS) Ovarian Cancer Patient Navigation Line:


    1-844-446-8727

    https://www.michigan.gov/mdhhs/ 


    Society of Gynecologic Oncology: Ovarian Cancer

    https://www.sgo.org/patient-resources/ovarian-cancer/


    Foundation for Women's Cancer: Ovarian Cancer

    https://www.foundationforwomenscancer.org/gynecologic-cancers/cancer-types/ovarian/


    NCCN Patient Guidelines: Epithelial Ovarian Cancer

    https://www.nccn.org/patients/guidelines/content/PDF/ovarian-patient.pdf


    American Cancer Society: Ovarian Cancer

    https://www.cancer.org/cancer/ovarian-cancer.html


    Center for Disease Control and Prevention: Ovarian Cancer

    https://www.cdc.gov/cancer/ovarian/index.htm


    Clinical Trials

    https://clinicaltrials.gov/


    Facing Our Risk of Cancer Empowered (FORCE)

    https://www.facingourrisk.org/


    Michigan Oncology Quality Consortium

    https://moqc.org/


    Michigan Ovarian Cancer Alliance (MIOCA)

    https://www.mioca.org/


    National Ovarian Cancer Coalition (NOCC)

    http://ovarian.org/


    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less

What listeners say about Chemotherapy, Part 2

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.